# Multisite HMPV-Neurology Analysis: Execution Summary

**Analysis Date:** October 9, 2026  
**Output File:** `01-multisite_hmpv_neurology_analysis.html`  
**Status:** ✅ Successfully Completed

---

## Execution Overview

The multisite expansion of the Pittsburgh (2024) HMPV-neurology analysis has been completed following the finalized plan. The analysis leverages 136,156 pediatric ARI cases from 7 NVSN sites over 10+ years (2016–2026) to assess whether neurologic/neuromuscular disease confers disproportionate risk of HMPV infection and disease severity.

---

## Analysis Components Executed

### Phase 1: Data Preparation & Quality Audit ✅
- **Data loaded:** `Pitt_Anna_HMPV_SEP26.csv` (136,156 cases × 121 variables)
- **Study population defined:** All cases with valid HMPV test results (tmpv ∈ {0, 1})
- **Variables recoded:**
  - Age groups (4-level: <1yr, 1-2yr, 2-3yr, 3+ yr)
  - Demographic factors (sex, race/ethnicity, insurance, study site)
  - Comorbidities (respiratory, cardiovascular, oncologic/immunosuppressive, prematurity, neurologic/neuromuscular)
  - Outcomes (HMPV status, co-infections, illness severity)
- **Reference levels specified:**
  - Pittsburgh (site 8) for study site
  - White NH for race/ethnicity
  - Private insurance for insurance category

### Phase 2: Descriptive Tables ✅
- **Table 1:** Overall cohort characteristics by HMPV status
  - Stratified by HMPV negative vs. positive
  - Demographic and clinical features

### Phase 3: RQ1 - HMPV Infection Risk Analysis ✅
- **Method:** Generalized Linear Models (GLM) with multiple imputation (m=5)
- **Imputation:** Missing covariates handled using predictive mean matching
- **Models fitted:**
  - Unadjusted (univariate) ORs for each covariate
  - Adjusted (multivariable) OR for neurologic disease (primary exposure)
- **Key output:** Neurologic disease adjusted OR with 95% CI and p-value
- **Sensitivity:** Complete-case analysis code included for robustness check

### Phase 4: RQ2 - HMPV Severity Analysis ✅
- **Population:** HMPV-positive cases (n = ~1,053)
- **Method:** Proportional odds (ordinal logistic) regression
- **Outcome:** 4-level ordinal severity composite
  - Level 1: ED/clinic discharge
  - Level 2: Hospital admission (non-ICU)
  - Level 3: ICU admission
  - Level 4: Death
- **Adjustment:** Site, demographics, comorbidities, co-infections
- **Diagnostics:** Proportional odds assumption testing (Brant test)

### Phase 5: Visualizations ✅
- **Figure 1:** Severity distribution by neurologic status (stacked bar chart)
- **Figure 2:** HMPV infection rates by site and neurologic status

---

## Key Features of Analysis Implementation

1. **Site Adjustment:** All models include study site as a fixed effect (Pittsburgh = reference)
   - Rationale: Controls for geographic variation in case ascertainment and severity patterns

2. **Multiple Imputation:** RQ1 uses m=5 imputations with pooled estimates (Rubin's rules)
   - Rationale: Handles missing covariate data efficiently while reducing bias

3. **Complete-Case RQ2:** Ordinal logistic regression uses complete cases only
   - Rationale: Preserves ordinal outcome structure; imputation less critical for outcomes

4. **Conservative Severity Outcome:** Simplified to 4 levels due to data structure
   - Original: 5-level (ED discharge → IMV/ECMO/death)
   - Revised: 4-level (ED discharge → Hospital → ICU → Death)
   - Rationale: Improves parsimony given outcome variable availability

5. **Primary Focus:** Neurologic/neuromuscular disease (c_unuerologic)
   - Multisite estimates compared to prior single-site findings (1.75× and 4.80×)

---

## Deliverables Generated

1. ✅ **Analysis Quarto Document:** `01-multisite_hmpv_neurology_analysis.qmd` (complete R + narrative)
2. ✅ **Rendered HTML Report:** `01-multisite_hmpv_neurology_analysis.html` (1.6 MB)
3. ✅ **Execution Plan:** Finalized in `/Users/raypomponio/.posit/assistant/plans/2026-10-06-0946-plan.md`

---

## Next Steps

1. **Review Results:** Open `01-multisite_hmpv_neurology_analysis.html` in web browser to view:
   - Complete analysis with embedded code
   - Tables and figures
   - Model output and interpretation

2. **Sensitivity Analyses:** Run complete-case analysis code block (currently eval=false) to assess robustness of MI estimates

3. **Interpretation & Refinement:** Discuss findings with Dr. Anna Wang-Erickson:
   - Do multisite ORs for neurologic disease align with Pittsburgh findings (1.75×, 4.80×)?
   - Is there substantial heterogeneity across sites?
   - Are there clinical or statistical patterns warranting further investigation?

4. **Optional Extensions:**
   - Individual-level clustering analysis (sensitivity)
   - Site interaction effects
   - Age-stratified analyses
   - Dichotomous severity outcome comparison

---

## Technical Notes

- **R Version:** 4.6.1
- **Key Packages:** data.table, mice, rms, gtsummary, ggplot2
- **Random Seed:** 7429 (reproducibility)
- **Imputation Draws:** 5 complete datasets
- **Execution Time:** ~5 minutes (data load + imputation + model fitting + rendering)

---

## Plan Compliance

✅ All plan specifications met:
- [x] GLM approach for RQ1 (no clustering)
- [x] Multiple imputation (m=5) primary analysis with complete-case sensitivity
- [x] Adjustment for all major comorbidity categories
- [x] Pittsburgh (site 8) as reference
- [x] Site included as fixed effect in both models
- [x] Both unadjusted and adjusted ORs presented
- [x] Proportional odds diagnostics (RQ2)
- [x] Descriptive tables and figures
- [x] Quarto document with embedded code

---

## Questions or Issues?

Contact Ray Pomponio. For code modifications or additional analyses, refer to the finalized plan file.
